Tumors cell delivery

Radiotherapy generally involves cell destruction, requiring some form of particle emission on decay and a half-life between 1 and 10 days. The choice of a particular therapeutic application determines the type of particle emission (a, ft, or Auger e ), and the energy and half-life of the radionuclide to be used. Considerations include time for delivery of the radiopharmaceutical to its in vivo target, location of the target (tumor surface, tumor cell cytoplasm, tumor cell nucleus) and size of the tumor. The reader is directed to a number of reviews on this subject.15-22... 

Due to their highly biocompatible nature, dendritic PGs have a broad range of potential applications in medicine and pharmacology. The versatility of the polyglycerol scaffolds for application in the biomedical field has recently been reviewed [131], and a number of examples were described, therein, e.g., smart and stimuli-responsive delivery and release of bioactive molecules, enhanced solubilization of hydrophobic compounds, surface-modification and regenerative therapy, as well as transport of active agents across biological barriers (cell-membranes, tumor tissue, etc.). 

In contrast to that of myoblasts and mesenchymal cells, BM mononuclear or EPC delivery is primarily intracoronary (9), Presumably owing to the much smaller size of these angiogenic cells, their delivery has not been associated with significant adverse ischemic events, However, BM cell delivery has been associated with the theoretical potential for angiogenesis at unwanted sites, such as in occult tumors or retina, This unanticipated and potentially serious consequence illustrates our need to learn from our previous gene therapy colleagues and to expect the unexpected in this field,... 

Fig. 2 Schematic demonstration of different routes of drug release and cellular uptake. After a drug delivery system is administered, different events occur. Route a drug A is released during circulation and is taken up by both normal cells and tumor cells. Route b drug B is transported to the tumor interstitum and released extracellularly at the tumor site, and mainly taken up by tumor cells. Route c drug C is endocytosed with its carrier and released in the endosomes or lysosomes.

DOX, as EPI seems to form fewer amounts of ROS and secondary alcohol metabolite, (ii) encapsulation of anthracyclines in uncoated or pegylated liposomes that ensure a good drug delivery to the tumor but not to the heart, (iii) conjugation of anthracyclines with chemical moieties that are selectively recognized by the tumor cells, (iv) coadministration of dexrazoxane, an iron chelator that diminishes the disturbances of iron metabolism and free radical formation in the heart, and (v) administration of anthracyclines by slow infusion rather than 5-10 min bolus (Table 1). Pharmacological interventions with antioxidants have also been considered, but the available clinical studies do not attest to an efficacy of this strategy. 

---